Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanxi Jinbo Bio pharmaceutical Co Gross Margin %?
Shanxi Jinbo Bio pharmaceutical CoBJSE:920982 78 Gross Margin % is 84.82% as of Mar. 2026, which is 0% below its 10-year median of 85.00. GuruFocus rates BJSE:920982 with a GF Score™ of 78/100 and a GF Value™ of ¥282.38 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, Shanxi Jinbo Bio pharmaceutical Co ranks better than 80.95% on this metric.
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shanxi Jinbo Bio pharmaceutical Co had a gross margin of 84.82% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Shanxi Jinbo Bio pharmaceutical Co Gross Margin % Related Terms
Shanxi Jinbo Bio pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Jinbo Bio pharmaceutical Co Gross Margin % Chart
BJSE:920982 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Shanxi Jinbo Bio pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Jinbo Bio pharmaceutical Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Jinbo Bio pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Shanxi Jinbo Bio pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) has a Gross Margin % of 84.82% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. This is near median its historical median of 85.00. Over the past decade, Shanxi Jinbo Bio pharmaceutical Co's Gross Margin % has ranged from 80.01 to 92.02. According to the industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #140 out of 735 companies in the Biotechnology industry, placing it in the top 19%.
Is Shanxi Jinbo Bio pharmaceutical Co's Gross Margin % too high?
Shanxi Jinbo Bio pharmaceutical Co's current Gross Margin % of 84.82% is near median its 10-year median of 85.00. Over the past 10 years, this metric has ranged from a low of 80.01 to a high of 92.02. The Biotechnology industry median Gross Margin % is 60.90. Shanxi Jinbo Bio pharmaceutical Co's value of 84.82% is 39.3% above this industry median. Based on the distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #140 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanxi Jinbo Bio pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Jinbo Bio pharmaceutical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #140 out of 735 companies for Gross Margin %. This places Shanxi Jinbo Bio pharmaceutical Co in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Shanxi Jinbo Bio pharmaceutical Co's value of 84.82% is 39.3% above this benchmark. Historically, Shanxi Jinbo Bio pharmaceutical Co's own Gross Margin % has ranged from 80.01 to 92.02 over the past decade. While the company's 10-year median is 85.00 vs. the industry median of 60.90, Shanxi Jinbo Bio pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanxi Jinbo Bio pharmaceutical Co's current Gross Margin % of 84.82% is 39.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanxi Jinbo Bio pharmaceutical Co's current Gross Margin % is 84.82%, which is near median its own 10-year median of 85.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Jinbo Bio pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥282.38, compared to a current price of ¥129.49 — trading 54.1% below its estimated fair value. The current Gross Margin % is 84.82%, which is near median its 10-year median of 85.00 and 39.3% above the Biotechnology industry median of 60.90. Shanxi Jinbo Bio pharmaceutical Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982), the current Gross Margin % is 84.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥129.49 is trading 54.1% below its estimated GF Value™ of ¥282.38.
GuruFocus considers Shanxi Jinbo Bio pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for BJSE:920982:
Gross Margin %: 84.82% (near median its 10-year median of 85.00)
GF Value™: ¥282.38 vs. price of ¥129.49 (54.1% below fair value)
Industry Position: 39.3% above the Biotechnology median (#140 of 735)
No single metric tells the full story. See the BJSE:920982 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Jinbo Bio pharmaceutical Co Ltd is engaged in research & development, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.
78GF Score
Get the complete analysis for BJSE:920982
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920982 has been successfully added to your 
